null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Milatuzumab ELISA Kit (GXEL00069)

SKU GXEL00069
Product Type ELISA Kit
Assay Type Quantitative
Detection Method Colorimetric
Sensitivity 0.156 μg/ml
Range 0.31-5 μg/mL
Size 96T
Synonyms CD74-DOX (ADC), MEDI-115, hLL1, hLL1-DOX (ADC), 899796-83-9
€880
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Milatuzumab ELISA Kit

The Milatuzumab ELISA Kit (SKU: GXEL00069) enables sensitive, reproducible quantitative detection of Milatuzumab in Plasma, Serum using a quantitative ELISA format. The assay delivers a detection range of 0.31-5 μg/mL and a sensitivity of 0.156 μg/ml and is read colorimetrically at 450 nm, making it well suited to quantitative research workflows.

Milatuzumab is a new immunotherapeutic agent targeting CD74, a membrane protein preferentially expressed in hematopoietic cancers and some solid tumors. Broad expression and fast internalization makes CD74 an ideal target for cancer therapy. We reviewed published articles about CD74 and milatuzumab. We present a comprehensive review of CD74 functions and provide explanation of milatuzumab antitumor effects. This review describes CD74 protein biology with the emphasis on the role of CD74 in tumor survival and its new role in regulation of the Fas death receptor. The development of CD74 targeting therapies to induce tumor regression and cancer cell apoptosis is described and results of clinical trials are discussed. Milatuzumab shows selective binding and rapid internalization into CD74-positive cancer cells. Milatuzumab with and without conjugated toxins synergizes with other chemotherapeutic agents and elicits significant antitumor effects in mice. In a Phase I trial, milatuzumab showed no severe adverse effects in patients with relapsed/refractory multiple myeloma and it stabilized the disease in some patients for up to 12 weeks. Ongoing trials testing different treatment schedules of milatuzumab in chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma indicate that milatuzumab shows no severe adverse effects in humans.

Supplied with pre-coated microplates and all core reagents, the Milatuzumab ELISA Kit gives you a validated, ready-to-use solution for Milatuzumab research. Get accurate and reliable results with the Milatuzumab ELISA Kit from Assay Genie.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose